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Abstract
Purpose To review the developments of recent decades and
the current status of PET molecular imaging in Huntington’s
disease (HD).
Methods A systematic review of PET studies in HD was
performed. The MEDLINE, Web of Science, Cochrane and
Scopus databases were searched for articles in all languages
published up to 19 August 2015 using the major medical
subject heading BHuntington Disease^ combined with text
and key words BHuntington Disease^, BNeuroimaging^ and
BPET .^ Only peer-reviewed, primary research studies in HD
patients and premanifest HD carriers, and studies in which
clinical features were described in association with PET neu-
roimaging results, were included in this review. Reviews, case
reports and nonhuman studies were excluded.
Results A total of 54 PETstudies were identified and analysed
in this review. Brain metabolism ([18F]FDG and [15O]H2O),
presynaptic ([18F]fluorodopa, [11C]β-CIT and [11C]DTBZ)
and postsynaptic ([11C]SCH22390, [11C]FLB457 and
[11C]raclopride) dopaminergic function, phosphodiesterases
([18F]JNJ42259152, [18F]MNI-659 and [11C]IMA107), and
adenosine ([18F]CPFPX), cannabinoid ([18F]MK-9470), opi-
oid ([11C]diprenorphine) and GABA ([11C]flumazenil) recep-
tors were evaluated as potential biomarkers for monitoring
disease progression and for assessing the development and
efficacy of novel disease-modifying drugs in premanifest
HD carriers and HD patients. PET studies evaluating brain
restoration and neuroprotection were also identified and
described in detail.
Conclusion Brain metabolism, postsynaptic dopaminergic
function and phosphodiesterase 10A levels were proven to
be powerful in assessing disease progression. However, no
single technique may be currently considered an optimal bio-
marker and an integrative multimodal imaging approach com-
bining different techniques should be developed for monitor-
ing potential neuroprotective and preventive treatment in HD.
Keywords Huntington’s disease . Premanifest Huntington’s
disease gene carriers . Neurodegeneration imaging . Positron
emission tomography
Introduction
Huntington’s disease (HD) is an autosomal dominant mono-
genic neurodegenerative disease with a prevalence of 0.4 – 5.7
per 100,000 worldwide [1]. HD is caused by an expanded
CAG trinucleotide repeat sequence in the huntingtin gene on
chromosome 4, which leads to the formation of intranuclear
inclusions of mutated huntingtin in the brain, resulting in loss
of GABAergic medium spiny neurons (MSNs) in the striatum
and in cortical areas [2]. HD is clinically characterized by
motor symptoms (chorea and parkinsonism), cognitive symp-
toms (slowedmentation, attention, mental flexibility, planning
and emotion recognition) and psychiatric symptoms (depres-
sion, apathy, impulsivity, irritability, disinhibition and psycho-
sis), with a progressive course and a typical onset in adult
middle age (40 – 55 years) [3]. The age at onset is inversely
correlated with the size of the CAG repeat expansion [4]. This
allows us to predict the motor onset [5] and classify the disease
in stages such as premanifest HD (before motor onset) and
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manifest HD (after motor onset) [6] providing a tremendous
opportunity to investigate subclinical and pathological chang-
es in asymptomatic HD gene carriers. This offers a therapeutic
window for potential preventive treatments aiming to delay
the clinical onset of HD.
The mechanisms underlying the progressive neurodegen-
eration in HD are still unclear and, currently, there is no single
proven biomarker that allows us to monitor disease progres-
sion and assess the efficacy of novel disease-modifying drugs.
The lack of biomarkers may be related to the fact that HD
pathology causes only minor brain alterations in early stages
[7].
Molecular imaging techniques are able to identify subtle
alterations at the nanomolecular level and this is a prerequisite
to understanding minimal changes in brain activity [8, 9]. PET
molecular probes bind a target, such as a receptor, a transport-
er or an enzyme, with high specificity and power of resolution
[10]. PET molecular imaging has revolutionized the ability to
gain insights into human brain biology and beyond this to
understand the physiology and pathophysiology of neurolog-
ical diseases [11]. PET radiotracers have provided invaluable
insights into the natural history of HD and have been used to
measure brain metabolism, dopaminergic function, neuroin-
flammation, phosphodiesterases and other targets in HD [12].
They have contributed to the identification of disease charac-
teristics at different stages mainly in cross-sectional studies
but also in some longitudinal studies.
This review describes the developments during recent
decades and current applications of PET molecular imaging
techniques in HD.
Methods
Search strategy
The MEDLINE, Web of Science, Cochrane CENTRAL and
Scopus databases were searched for articles in all languages
published up to 19 August 2015. Studies were identified and
evaluated by two of the authors (G.P. and F.N.) using the
major medical subject heading BHuntington Disease^ com-
bined with text and key words BHuntington Disease^,
BNeuroimaging^ and BPET .^ Additional eligible studies were
identified by screening the reference lists of the studies found.
Inclusion criteria
Studies were excluded if the title and/or abstract was not ap-
propriate for the aim of the review. The full text of eligible
studies and of studies whose relevance was uncertain were
obtained. Selected studies were eligible if they met the follow-
ing criteria: (1) peer-reviewed, primary research studies, (2)
studies including HD patients, (3) studies including a
description of the clinical features of the HD patients in asso-
ciation with neuroimaging results, and (4) studies including
PET neuroimaging. Reviews, case reports and nonhuman
studies were excluded.
Results
Of 944 articles identified by the initial search, 86 were re-
trieved for more detailed evaluation, and 54 PET studies were
finally identified and analysed in this review. The results of 32
of the main studies are summarized in Table 1.
Brain metabolism
[15O]H2O and [
18F]FDG have been used as markers of cere-
bral blood flow and cerebral glucose metabolism providing an
index of neuronal integrity and the functional state of neurons
[13]. Changes in motor-related cortical activation have been
evaluated using [15O]H2O PET [14, 15]. In manifest HD, im-
paired activation of the striatum and its frontal motor projec-
tion areas during motor tasks, such as paced joystick move-
ments or sequential finger-to-thumb opposition, has been
found. There was a parallel increased activity in the parietal
areas [14] and insular areas [15]. These findings suggest that
the loss of MSNs in the striatum leads to impairment of the
basal ganglia-thalamocortical motor output and may induce a
compensatory recruitment of additional accessory motor path-
ways [14, 15]. Moreover, different patterns of brain activation
have been shown in HD patients during word generation task
[16]. During the word generation task, HD patients show de-
creased cerebral blood flow in the anterior cingulate and the
inferior frontal gyri (related to lexical selection) and a com-
pensatory activation of the left supramarginal gyrus and the
right inferior frontal gyrus, suggesting the presence of
compensatory language strategies in HD [16].
[18F]FDG studies in manifest HD patients have shown glu-
cose hypometabolism in the striatum and the cortex [17–19].
Striatal hypometabolism was associated with motor dysfunc-
tion [20], and cortical hypometabolism with cognitive dys-
function [19, 21]. Striatal and cortical hypometabolism has
also been found to precede neuronal loss in premanifest HD
gene carriers [22–24]. However, it has been suggested that a
possible hypermetabolism precedes the decrease in these areas
[25]. Moreover, [18F]FDG hypometabolism was not localized
in a specific area, and an approach using a network of regions
with altered metabolism has been used to identify spatial co-
variance patterns in premanifest HD [25–28]. Following this
approach, relative bilateral increases in thalamic, occipital and
cerebellar glucose metabolism associated with bilateral de-
creases in striatal metabolism has been identified as a charac-
teristic pattern of HD, which discriminated well between HD
patients and healthy controls [26]. This characteristic pattern
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Table 1 Main PET studies in Huntington’s disease
Year Reference Study population PET tracer Molecular target Main findings
Brain metabolism
1997 [15] 7 HD, 7 HCs [15O]H2O Regional cerebral
blood flow
Deficit in the task-related activation in the striatum and
its frontal motor area projections
1990 [19] 23 HD, 21 HCs [18F]FDG Glucose uptake Decrease in caudate and cortical metabolism.
Correlation with cognitive dysfunction
1996 [17] 8 HD, 10 pre-HD,
previous HCs
[18F]FDG, [11C]
raclopride
Glucose uptake,
D2 receptors
Lower loss of glucose uptake than of D2 receptor levels
(2.3 % vs. 6.3 % per year)
2006 [23] 47 HD, 24 pre-HD,
30 HCs
[18F]FDG Glucose uptake Decrease in caudate and cortical metabolism in HD
patients and in pre-HD patients. Hypometabolism
in pre-HD patients preceded volume loss
2012 [24] 46 pre-HD [18F]FDG Glucose uptake Lower caudate metabolism in patients with pre-HD
converted to HD than in patients with pre-HD not
converted (5-years follow-up)
2013 [28] 12 pre-HD, 12 HCs [18F]FDG, [11C]
raclopride
Glucose uptake,
D2 receptors
Progressive alterations of striatothalamic and cortical
metabolic activity network in pre-HD patients
Dopaminergic function
1994 [36] 5 HD, 1 pre-HD,
5 HCs
[11C]SCH 23390 D1 receptors Decrease (75 %) in striatal D1 receptors density in HD
patients
1995 [39] 10 HD patients,
9 HCs
[11C]SCH 23390,
[11C]raclopride
D1 receptors,
D2 receptors
Decrease in striatal D1 and D2 receptors in HD patients.
Akinetic-rigid patients had greater D1 and D2
receptor loss in the striatum than choreic HD patients
1997 [33] 5 HD, 5 HCs [11C]SCH 23390,
[11C]raclopride,
[11C]β-CIT
D1 receptors,
D2 receptors,
DAT
Decrease in striatal D1 and D2 receptors and striatal
DAT binding. Correlation between D2 receptor loss
and duration of symptoms
1998 [45] 8 HD, 10 pre-HD [11C]Raclopride D2 receptors Decrease in D2 receptors in the striatum of pre-HD
patients. Correlation between D2 receptor loss and
CAG repeat length
1998 [43] 17 pre-HD [11C]SCH 23390,
[11C]raclopride
D1 receptors,
D2 receptors
Decrease in striatal D1 and D2 receptors in pre-HD
patients. Correlation between D1 and D2 receptor loss
and cognitive dysfunction
1999 [37] 4 HD, 9 pre-HD,
7 HCs
[11C]SCH 23390,
[11C]raclopride
D1 receptors,
D2 receptors
Decrease in striatal D1 and D2 receptors in pre-HD
patients. Correlation between D1 and D2 receptor loss
and UHDRS
2000 [34] 19 HD, 64 HCs [11C]DTBZ VMAT2 Decrease in VMAT2 binding in caudate (30 %) and
putamen (60 %)
2005 [38] 27 pre-HD [11C]Raclopride,
[18F]FDG
D2 receptors,
glucose uptake
Decrease (50 %) in D2 receptors in the striatum of
pre-HD patients. Correlation between D2 receptor
loss and increases in the product of age and CAG
repeat length
2006 [40] 12 HD, previous HCs [11C]Raclopride D2 receptors Decrease in D2 receptors in the amygdala, and temporal
and frontal cortex in HD patients
2008 [44] 9 HD, 10 pre-HD,
10 HCs
[11C]Raclopride,
[11C]PK11195
D2 receptors,
TSPO
Decrease in D2 receptors in the hypothalamus of HD
and pre-HD patients. Correlation between D2
receptor loss and increased activation of microglia
2010 [42]a 16 HD, 11 pre-HD,
previous HCs
[11C]Raclopride D2 receptors Decrease in D2 receptors in the cortex of HD and
pre-HD patients. Correlation between D2 receptor
cortical levels and cognitive dysfunction
2011 [35] 9 HD, 9 HCs [11C]FLB457 D2 receptors Decrease in D2 receptors in the striatum but not in
extrastriatal areas. Correlation between striatum D2
receptor loss and motor symptoms
Activation of microglia
2006 [51]a 11 HD, 10 HCs [11C]PK11195,
[11C]raclopride
TSPO, D2
receptors
Increase in activation of microglia in striatal and cortical
areas in HD patients. Correlation between increased
TSPO and loss of D2 receptors in the striatum and
with motor dysfunction (UHDRS)
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Table 1 (continued)
Year Reference Study population PET tracer Molecular target Main findings
2007 [52]a 11 pre-HD, 10 HCs [11C]PK11195,
[11C]raclopride
TSPO, D2
receptors
Increase in activation of microglia in striatal and cortical
areas in pre-HD patients. Correlation between
increased TSPO and loss of D2 receptors in the
striatum
2011 [53]a 8 pre-HD, 8 HCs [11C]PK11195,
[11C]raclopride
TSPO, D2
receptors
Increase in activation of microglia in striatal and cortical
areas in pre-HD patients. Correlation between
increased TSPO in associative striatum and cognitive
dysfunction
2015 [54]a 12 pre-HD, 12 HCs [11C]PK11195 TSPO Increase in activation of microglia in cortical regions,
basal ganglia and thalamic region in pre-HD patients.
Correlation between increased TSPO and plasma
levels of IL-1β, IL-6, IL-8 and TNF-α. First in vivo
evidence of an association between peripheral and
central immune responses in pre-HD patients
PDE10A
2014 [59] 5 HD, 11 HCs [18F]JNJ42259152 PDE10A Decreases in PDE10A of 70.7 % and 62.6 % in the
caudate and putamen, respectively. No correlations
between PDE10A and clinical scales
2014 [60] 8 HD, 3 pre-HD,
9 HCs
[18F]MNI-659 PDE10A Decreases in PDE10A of 50 % in the striatum of
manifest HD patients compared with HCs. Pre-HD
patients had values intermediate between HD patients
and HCs. Striatal correlations between PDE10A and
severity of disease measured by the clinical scale
(UHDRS, motor subscale), the molecular marker
(BOP), and regional atrophy
2015 [61] 12 pre-HD, 12 HCs [11C]IMA107 PDE10A Decreases in PDE10A of 30 % in the striatum and 25 %
in the pallidus, and increase of 35 % in motor
thalamic nuclei in pre-HD patients
Adenosine and cannabinoid receptors
2014 [64] 8 HD, 6 pre-HD-Bb,
7 pre-HD-Ac,
36 HCs
[18F]CPFPX A1 receptors Cerebral A1 receptor levels in pre-HD-A patients were
higher than in HCs (by up to 31 % in the thalamus).
Successive reduction in A1 receptor binding in pre-
HD-B patients compared with HCs and binding in
manifest HD patients lower than in HCs (decrease to
25 % in the caudate and amygdala). Strong
correlation between A1 receptor binding and years
since onset
2010 [73] 20 HD, 14 HCs [18F]MK-9470,
[18F]FDG
CB1 receptors,
glucose uptake
Decrease in CB1 receptors in the cerebrum and
cerebellum (grey matter) and brainstem
Opioid and GABA receptors
1993 [71] 6 HD, 6 HCs [11C]Flumazenil,
[18F]FDG
GABA receptors,
glucose uptake
Decrease in GABA receptors in the caudate and
decrease in glucose uptake in the caudate putamen
and thalamus
2000 [72] 10 HD, 13 pre-HD [11C]Flumazenil,
[18F]FDG, [11C]
raclopride
GABA receptors,
glucose uptake,
D2 receptors
Decrease in GABA receptors in the caudate and
decrease in glucose uptake and D2 receptors in the
caudate, putamen and thalamus in HD patients.
Reduction in GABA receptors was significantly less
in manifest HD patients than in pre-HD patients with
normal D2 receptor levels, but not in comparison with
pre-HD patients with reduced D2 receptor levels
1997 [77] 2 HD, 9 HCs [11C]Diprenorphine Opioid receptors Decrease in opioid receptors in the caudate and putamen
A1 adenosine type 1, CB1 cannabinoid type 1,D1 dopaminergic type 1,D2 dopaminergic type 2,HC healthy controls, PDE10A phosphodiesterase 10A,
UHDRS unified Huntington’s disease rating scale
a Cortical changes were not present in all the patients included in this study
b pre-HD-B: near predicted symptom onset
c pre-HD-A: far from predicted symptom onset
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has shown good reliability as a marker of disease progression
although there was a tendency to be quite stable after an initial
impairment (nonlinear trend), thus limiting its clinical utility
[26]. Reduction in [18F]FDG uptake in the striatum, and fron-
tal, parietal and temporal cortex indicates an impairment in
intracellular processes, such as calcium handling, transcription
regulation and mitochondrial energy production, while an in-
crease in [18F]FDG uptake in the thalamus, and occipital and
cerebellar cortex might indicate an increased glycolytic re-
sponse due to mitochondrial dysfunction [25] or due to the
lack of inhibitory activity exerted by the damaged basal
ganglia on the thalamocortical system [26].
Dopaminergic function
Pathognomonic chorea and the other motor features (parkin-
sonism and dystonia) of HD are related to impairment in do-
paminergic function [29]. The neurodegenerative process
mainly affects the striatal MSNs expressing dopaminergic
type 1 (D1) and type 2 (D2) receptors [30]. This leads to severe
involvement of the postsynaptic dopaminergic system with
relatively spared presynaptic dopaminergic nerve terminals.
However, presynaptic dopaminergic function in HD has been
investigated only in small and older studies, with discordant
results. In manifest HD patients, caudate [18F]fluorodopa up-
take (targeting dopa decarboxylase) has been found to be re-
duced [31] or normal [32], [11C]β-CIT levels (targeting
striatal dopamine transporter) were 50 % reduced [33] and
[11C]DTBZ levels (targeting type-2 vesicular monoamine
transporter) showed a gradient from a rostral increase to a
caudal decrease in the striatum [34]. However, in these PET
studies no correction for partial volume effects was performed
and their results may have been affected by regional volume
loss, and thus it is unclear whether they measured degenera-
tion of neurons or pure presynaptic dopaminergic terminal
dysfunction. Presynaptic dopaminergic function has not been
investigated in premanifest HD patients, nor has the associa-
tion with CAG repeat expansion or other HD-related clinical
features.
Postsynaptic dopaminergic dysfunction is a key character-
istic of HD. This has been investigated using [11C]SCH22390
as marker of D1 receptors density and using [
11C]raclopride
and [11C]FLB457 [35] as markers of D2 receptor density. The
densities of D1 and D2 receptors were significantly reduced in
the striatum, ranging from 40 % [33] to 75 % [36] in HD
patients and from 25 % [37] to 50 % [38] in premanifest HD
gene carriers. This loss was found to be higher in akinetic-
rigid HD patients than in choreic manifest HD patients [39].
Reductions in striatal D1 and D2 receptors were also correlated
with worse motor dysfunction, as assessed using the unified
Huntington’s disease rating scale (UHDRS) [37, 40]. In
extrastriatal areas, a reduction in D1 receptors has been found
in the temporal cortex and was associated with cognitive
dysfunction in manifest HD patients [33, 41]. In a study using
[11C]raclopride including 16 manifest HD patients and 11
premanifest HD gene carriers [42], the cortical D2 receptor
levels were reduced in both manifest HD patients and
premanifest HD gene carriers and were associated with the
degree of cognitive dysfunction (attention and executive func-
tions). In line with these results, another study using
[11C]raclopride [40] showed a reduction in D2 receptor levels
in the amygdala, and frontal and temporal cortex of 12 man-
ifest HD patients. Levels of both D1 and D2 receptors (but
mainly D2 receptors) were strongly correlated with cognitive
performance in 17 premanifest HD gene carriers [43].
Hypothalamic D2 receptor levels were also significantly re-
duced in presymptomatic and premanifest HD gene carriers
[44]. The early involvement of the hypothalamus might ex-
plain the prodromal nonmotor symptoms and could be a po-
tential early biomarker in HD. The number of CAG repeat
lengths has been associated with a reduction in striatal D2
receptor levels in premanifest HD patients [38, 45], suggesting
that mutant huntingtin plays a role in the expression of dopa-
mine receptors. These findings support the primary involve-
ment of sensorimotor striatum dysfunction in the motor com-
ponent of the disease [40] and of associative striatum and
temporal cortex dysfunction in the cognitive component of
the disease [42], with D2 receptor loss as the common
biological substrate.
Activation of microglia
Activation of microglia is considered one of the mechanisms
underlying neurodegeneration [46]. However, it is not clear if
it represents a compensatory mechanism for neuronal loss or a
trigger of damage [47]. Microglia release cytokines when
stimulated by abnormal proteins, such as mutant huntingtin.
These cytokines are proinflammatory and further stimulate
microglia, resulting in a self-propagating cascade, which
may lead to neuronal dysfunction and death [48]. This process
is not confined to the brain, but peripheral plasma cytokines
are also increased in premanifest and manifest HD gene car-
riers [47]. Activation of microglia can be measured using
18-kDa translocator protein (TSPO) ligands, such as
[11C]PK11195, [11C]GE180, [11C]PBR28, and others [49].
So far only [11C]PK11195 has been used to measure TSPO
in HD gene carriers. [11C]PK11195 is a first-generation TSPO
PET ligand, whereas the others were developed recently and
represent second-generation TSPO PET [50]. Increased acti-
vation of striatal and cortical microglia has been found in
manifest HD gene carriers [51] and in premanifest HD gene
carriers and was associated with loss of striatal D2 receptors
([11C]raclopride binding) [52]. In manifest HD patients,
striatal TSPO levels are also associated with motor dysfunc-
tion (UHDRS) [52]. In a more recent study, increased TSPO
binding has been observed specifically in the associative
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striatum of premanifest HD patients and correlated with cog-
nitive dysfunction [53]. We have also recently demonstrated
that plasma levels of IL-1β, IL-6, IL-8 and TNF-α are corre-
lated with increased [11C]PK11195 binding in the somatosen-
sory cortex of premanifest HD patients [54]. These findings
demonstrate for the first time in vivo a link between peripheral
and central immune dysfunction and support the role of im-
mune dysfunction in the pathogenesis of HD. In terms of
pathology, it is reasonable to assume that the more dorsal part
of the striatum (related to motor and cognitive function) is
affected earliest in HD, whereas the ventral part of the striatum
(related to psychiatric function) is affected later, possibly after
the onset of motor symptoms [53].
Phosphodiesterases
Phosphodiesterases are a family of intracellular enzymes hy-
drolysing cyclic nucleotides (cAMP and cGMP) [55].
Phosphodiesterase 10A (PDE10A) is mainly expressed in
striatal MSNs where it regulates the cAMP/PKA/DARPP-32
signalling cascade, and thus plays a key role in the regulation
of striatal output and in promoting neuronal survival [55, 56].
PDE10A has received increasing attention after the observa-
tion that its pharmacological inhibition in an animal model of
HD significantly improves HD symptoms and pathology [57].
Post-mortem studies have confirmed that PDE10A is severely
reduced in manifest HD patients [58].
[18F]JNJ42259152, [18F]MNI-659 and [11C]IMA107 have
been used to quantify of PDE10A expression in vivo in HD
patients [59–61]. In five manifest HD patients, Ahmad et al.
[59] found 70.7 % and 62.6 % [18F]JNJ42259152 binding
reductions in the caudate and putamen, respectively (Fig. 1).
Thes e au t ho r s found no co r r e l a t i on s be tween
[18F]JNJ42259152 levels and clinical scales. Russell et al.
[60], found 47.6. % decreases in striatal and pallidal
[18F]MNI-659 binding in eight patients with early manifest
HD. Lower striatal [18F]MNI-659 bindingwas associatedwith
worse UHDRSmotor scores, disease burden of pathology and
regional atrophy. In three premanifest HD gene carriers, who
were a mean of 12 years from predicted onset, striatal
PDE10A expression was also found to be decreased although
to a lesser degree compared to the group of manifest HD
patients [60].
Using [11C]IMA107 PET, our group has recently investi-
gated PDE10A expression in 12 HD gene carriers with early
premanifest asymptomatic HD who were a mean of 25 years
before the predicted onset of motor symptoms [61]. We found
25 – 33 % reductions in striatal and pallidal [11C]IMA107
binding, and 35 % increases in the motor thalamic nuclei.
We then combined PETand diffusor tensor imagingMRI data
to perform a connectivity-based striatal parcellation analysis
of PDE10A expression according to (a) cortex–striatum con-
nectivity profiles and (b) striatal connections with the globus
pallidus externus and substantia nigra/globus pallidus
internus, which reflect the major parts of the indirect and
direct pathways, respectively. We found that PDE10A de-
creases were confined to the sensorimotor striatum and to
the striatonigral and striatopallidal projecting segments.
Moreover, the altered balance of PDE10A expression between
the motor thalamic nuclei and the striatopallidal internal
projecting segments of the striatum was strongly associated
with the predicted risk of symptomatic conversion. Our find-
ings are a major breakthrough in the field of HD in showing
the earliest biochemical abnormality identified in HD to date,
and showing bidirectional alteration of PDE10A expression
within the neuropathological salient networks in HD gene
carriers up to 43 years before the development of overt clinical
symptoms, which are crucial to prognosis. These findings
provide in vivo evidence that PDE10A plays a role in the
pathophysiology of HD, although longitudinal studies are
needed to confirm the relationship between PDE10A and
clinical symptomatology.
Adenosine and cannabinoid receptors
The identification of novel targets is a primary objective of
current PET research in HD. Type 1 adenosine (A1) and type 1
cannabinoid (CB1) receptors represent only a few among
Fig. 1 Example PET images in healthy controls (HC) and premanifest
Huntington’s disease gene carriers (preHD). Axial [11C]MePPeP,
[11C]IMA107, [11C]raclopride images in stereotaxic space overlaid onto
the T1-weighted MNI template show decreased cortical CB1 receptor,
striatal PDE10A and striatal D2 receptor binding in the preHD subjects
compared to the healthy controls . Images from our data
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many potential novel targets that have recently become
investigable with PET imaging. In animal studies, adenosine
was increased by about 50 % in a mouse model of HD [62],
and A1 receptor levels in the hypothalamus were found to be
lower in HD rats carrying 51 CAG repeats [63]. [18F]CPFPX
has been used as a marker of A1 receptors in HD [64].
Matusch et al. [64] found a 25 % reduction in [18F]CPFPX
binding in the caudate of eight manifest HD patients (Fig. 1).
They studied premanifest HD patients, dividing them into
premanifest gene carriers far from predicted symptom onset
(preHD-A; n = 7) and near to predicted symptom onset
(preHD-B; n = 6). Interestingly, in preHD-A patients,
[18F]CPFPX binding in the thalamus was 31 % higher than
in healthy controls, while in preHD-B patients, thalamic
[18F]CPFPX binding was similar to the levels in healthy con-
trols. There was a strong correlation between A1 receptor
binding and years to onset [65]. These findings suggest that
A1 receptors switch from supranormal to subnormal levels
during phenoconversion of HD. This differential regulation
may play a role in the pathophysiology of altered energy
metabolism.
CB1 receptors are mainly expressed in GABA-ergic striatal
MSNs [65] (also expressing D1 and D2 receptors) and are a
key modulator of inhibitor neurotransmission [66]. In post-
mortem studies in manifest HD patients, a reduction in CB1
receptor levels was demonstrated in the striatum [67] and
GABA receptors were decreased in the caudate and putamen
and increased in the globus pallidus [68] and substantia nigra
[69]. This indicates that output GABAergic projections from
the striatum are severely affected in HD patients [70]. This
hypothesis has been confirmed in vivo in PET studies con-
ducted to evaluate GABA/benzodiazepine receptors [71, 72]
and CB1 receptors [73].
[18F]MK-9470 has been used as a marker of CB1 recep-
tors in PET studies of the cannabinoid system in HD [73].
Van Laere et al. [73] found reduced CB1 receptor binding
in the grey matter of the cerebrum and cerebellum, and in
the brainstem of 20 patients with manifest HD (Fig. 1).
They used a simplified semiquantification model and their
findings need to be confirmed in a full quantification
model. The widespread CB1 receptor changes observed
in HD are in line with the suppressive effect of mutant
huntingtin on CB1 transcription [74]. This finding strong-
ly suggests that cannabinoid dysfunction is heavily
involved in HD even during the early presymptomatic
stages of the disease.
Opioid and GABA receptors
Old targets, such as opioid and GABA, might be reintroduced
in combination with novel ones. Post-mortem studies have
shown that the opioid system is also affected in HD [75, 76].
A loss of encephalin of striatal projection neurons to the
external globus pallidus has been reported in premanifest
HD [75] and a reduction in the proencephalin/prodynorphin
ratio in the caudate, putamen, and internal and external globus
pallidus has been found in manifest HD patients [76].
[11C]Diprenorphine has been used as a marker of opioid re-
ceptor in HD [77]. Significant reductions of 31 % and 26 % in
[11C]diprenorphine binding in the caudate and putamen, re-
spectively, were demonstrated in five manifest HD patients
[77]. These reductions were lower than striatal dopaminergic
degeneration (about 60 % in manifest HD [39]), suggesting
that opioid receptor sites are less vulnerable to disease pro-
cesses than dopamine sites, possibly because of preservation
of presynaptic opioid sites.
[ 11C]Flumazeni l has been used as marker of
GABA/benzodiazepine receptors [71, 72]. Holthoff et al.
[71] found a 17 % reduction in [11C]flumazenil binding in
the caudate of six manifest HD patients, with normal putamen
and thalamic binding. They also found a reduction in
[18F]FDG binding of 47 %, 41 %, 18 % in the caudate, puta-
men and thalamus, respectively. In ten manifest HD patients,
Künig et al. [72] found the same results, showing reduced
[11C]flumazenil binding in the caudate (with normal values
in the putamen) and reduced [18F]FDG binding in the caudate
and putamen. The metabolic impairment of the putamen and
thalamus, without detectable loss of benzodiazepine receptor
density, confirms that the reduction in [18F]FDG uptake hap-
pens before the changes in [11C]flumazenil binding. Künig et
al. also compared [11C]flumazenil and [18F]FDG binding with
[11C]raclopride binding in 13 premanifest HD patients.
[11C]Raclopride binding in the caudate and putamen was re-
duced in all manifest HD patients and in eight premanifest
patients. As previously reported, a reduction in D2 receptor
levels indicates neuronal cell loss. Thus, they divided
premanifest gene carriers into two groups: those with and
those without a decrease in [11C]raclopride. [11C]Flumazenil
binding in the caudate was significantly lower in manifest HD
patients compared with premanifest patients without a de-
crease in [11C]raclopride, but not compared with those with
a decrease in [11C]raclopride who displayed [11C]flumazenil
values between those of the control subjects and the manifest
HD patients. These findings indicate that the loss in
pallidocaudate GABA projections was marked only in mani-
fest HD patients. [11C]Flumazenil binding in the putamen was
not different among healthy controls, and premanifest and
manifest HD gene carriers. The authors suggest that the nor-
mal [11C]flumazenil binding in the putamen of manifest HD
patients might be a compensatory mechanism in the pallidal
projection areas of striatal GABAergicMSNs. However, these
PET studies were not corrected for partial volume effects and
the results may have been affected by regional volume loss.
No studies investigating the cannabinoid system in
premanifest HD gene carriers have been published.
Interestingly, CB1 receptors and PDE10A transcription is
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modulated by huntingtin and, in HD animal models express-
ing a mutant huntingtin, CB1 receptors and PDE10A were
strongly reduced [78]. This reduction was present not only
in the symptomatic stage but also in the asymptomatic stage,
even before decreases in glucose uptake. Thus, these proteins
may not only be excellent biomarkers of HD progression but
may also represent novel therapeutic targets for HD.
Progression monitoring
Several longitudinal studies have been conducted in HD pa-
tients to identity biomarkers, monitor disease progression and
evaluate novel treatments. Brain metabolism and dopaminer-
gic function have been evaluated as potential PET biomarkers.
In a longitudinal study, Feigin et al. [26] observed a progres-
sive decline in [18F]FDG uptake across three time-points over
4 years. A recent [18F]FDG PET study has shown that
premanifest HD gene carriers who become symptomatic after
5 years following a PET scan have a mean glucose uptake in
the caudate significantly lower than those who do not convert,
and this difference is independent of CAG repeats [24]. These
findings suggest that brain metabolic changes may be predic-
tors of HD symptomatic conversion. Decreased cortical me-
tabolism in the early stage of HD is considered indicative of
rapid progression [79]. Indeed, cortical metabolism in the
frontotemporal and parietal cortices is significantly lower in
patients with early HD with faster progression of the disease
as measured using the Independence Scale of the UHDRS
[79].
A distinct spatial covariance pattern has been identified by
Tang et al. [28] as associated with disease progression using
longitudinal metabolic imaging data in premanifest HD
patients. This pattern showed a progressive impairment in
striatothalamic and cortical metabolic activity over 7 years
and was not influenced by symptomatic conversion.
Moreover, premanifest HD patients at higher risk of symptom-
atic conversion were those with higher metabolic network
activity at baseline [28]. Thus, metabolic network may be a
sensitive biomarker for disease progression during presymp-
tomatic stages.
In a combined [18F]FDG and [11C]raclopride longitudinal
study, premanifest HD gene carriers showed an annual loss of
2.3 % in striatal glucose metabolism and 6.3 % in D2 receptor
binding [17]. These findings suggest that glucose metabolism
is a less sensitive marker of disease progression than
[11C]raclopride [17]. In another longitudinal study, the decline
in D2 receptor levels was constant (around 5 % per year) [40],
although no correlation between changes in UHDRS motor
scores and reductions in striatal binding were observed [40].
This may be explained by the sigmoid model, in which the
motor symptoms reach a plateau (threshold of caudate degen-
eration/hypometabolism) and further degeneration is not asso-
ciated with worsening of symptoms. In premanifest HD
patients, longitudinal [11C]raclopride studies have shown rates
of decline from 4 % [37] up to 6.3 % [17]. In a 40-month
longitudinal study [37], nine premanifest HD patients and four
manifest HD patients showed a mean annual D1 receptor bind-
ing reductions of 2 % and 5 %, respectively, and D2 receptor
binding reductions of 4 % and 3 %, respectively [37]. Among
them, premanifest HD patients with annual losses ≥5 % dem-
onstrated faster disease progression. Thus, striatal D1 and D2
receptor binding may be used to identify asymptomatic HD
subjects with a higher risk of conversion [37]. However, in
another study [80] reduction in putaminal dopamine D2 recep-
tor binding was weakly correlated with the probability of
symptomatic conversion within 5 years, as calculated using
a model based on age and CAG repeats, and the rate of change
of putaminal D2 receptor binding was not increased around
the time of HD symptom onset [80]. Striatal degeneration
might proceed in a non-linear fashion in HD. A correlation
between CAG repeat length and the estimated percentage loss
of striatal D2 receptor binding were found in a cross-sectional
study among premanifest and manifest HD subjects [45].
However, while CAG repeat length influenced the rate of
disease progression, the slopes of the correlation for
premanifest and manifest HD population were significantly
different, suggesting that the rate of disease progression is
faster during the earlier asymptomatic stages of the disease
[45]. Therefore, striatal D2 receptor measures should be used
mainly in patients during premanifest HD stages, when they
are more sensitive.
Recently, novel biomarkers have been used to monitor dis-
ease progression. Russell et al. [81] found reduced striatal
[18F]MNI-659 uptake of about 50 % at baseline in eight man-
ifest HD patients compared with seven healthy controls. At
1 year, [18F]MNI-659 uptake had declined in the basal ganglia
in all eight manifest HD patients with mean annualized rates
of reduction in of 16.6 % in the caudate, 6.9 % in the putamen,
and 5.8 % in the globus pallidus. A decline in clinical status as
assessed using UHDRS was also observed in this cohort. To
date, three subjects had completed imaging assessment at
2 years and they showed a mean annualized reduction in
[18F]MNI-659 uptake at similar rate to that found at 1 year
(caudate 15.5 %, putamen 7.2 %, and globus pallidus 9.4 %).
Despite these promising results, head-to-head studies need to
be performed comparing [18F]MNI-659 with [18F]FDG and
[11C]raclopride to finally determine which functional PET
markers are most sensitive for monitoring HD progression.
Differences found between HD patients and healthy sub-
jects in the uptake of PET tracers in various brain regions are
summarized in Table 2.
Unfortunately, current biomarkers did not show consistent
results in terms of changes over time, thus limiting their utility
as markers of disease progression. A novel model (sigmoid
acceleration–deceleration) recently applied in Alzheimer’s
disease [82] might also be useful in HD. This model has been
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suggested to identify biomarkers with a nonlinear reduction
over time and assumes an initial acceleration of volume loss
up to an inflection point following which deceleration of atro-
phy occurs [82]. The pathophysiological changes in HD ex-
tend far beyond the striatum, cortical changes occur even at
the earliest stages of the disease. Using structural MRI, corti-
cal thinning has been found in early manifest HD patients [83]
and cortical degeneration of premotor and supplementary mo-
tor areas has been found to be associated with bradykinesia
[84]. Functional MRI studies have shown reorganization of
cortical circuitry at the early stage of HD [85]. Using an
Binterference^ task that activates multiple brain regions in-
cluding the anterior cingulate, inferior parietal, inferior tem-
poral, sensorimotor, premotor and inferior frontal cortices,
different patterns of brain activation have been found in
premanifest HD gene carriers further from disease onset
(increased activation) compared with premanifest HD gene
carriers closer to disease onset (reduced activation) [85].
Brain restoration
Brain metabolism and dopamine receptors levels have been
used to assess the efficacy of restorative therapy in HD pa-
tients. A multicentre open-label pilot study was designed to
evaluate the safety and efficacy of bilateral fetal striatal trans-
plantation [86]. Transplantation was performed in five HD
patients who were followed clinically and with PET over
3 – 10 years [87, 88]. No significant differences were found
over time using the UHDRS between patients who had and
had not received the transplant and striatal D1 and D2 receptor
binding indicated that there was no obvious surviving striatal
graft tissue [87, 88]. A 2-year follow-up study with [18F]FDG
in five HD patients who underwent bilateral striatal transplan-
tation [89, 90] was performed to assess the restoration of
striatocortical function [90]. Three patients showed an in-
crease in striatal/cortical glucose metabolic rate, associated
with clinical improvement or stabilization suggesting restora-
tion of striatocortical function. However, a 2-year follow-up
multicentre study failed to show significant this change in
[18F]FDG uptake [87]. Therefore, whether bilateral striatal
transplantation may restore striatocortical connections
remains a matter of debate [91, 92].
Neuroprotective drugs
Brain metabolism has been used to assess the efficacy of po-
tential neuroprotective drugs in HD. A randomized-controlled
trial using riluzole was performed in 23 HD patients (11 treat-
ed with riluzole and 12 with placebo) [93]. After a mean
follow-up of 24 months placebo-treated patients showed a
significantly greater proportional volume loss of grey matter
and decrease in metabolic [18F]FDG uptake than patients
treated with riluzole in all cortical areas. The decreased rate
of metabolic [18F]FDG uptake correlated with worsening clin-
ical scores in placebo-treated patients [93]. A small open-label
trial using pridopidine was performed in eight HD patients
[94] and increased metabolic activity in several brain regions
including the precuneus and mediodorsal thalamic nucleus
was found after treatment [94]. Memantine was investigated
in an open-label pilot trial in four HD patients and no differ-
ences in cortical or striatal metabolism were found between
before and after treatment [95].
Conclusion
There are no treatments currently available to stop disease
progression in HD. Brain metabolism (relative bilateral in-
creases in thalamic, occipital and cerebellar glucose
Table 2 PET tracer uptake changes in different brain area of HD patients compared with HC subjects
Brain target Tracer Caudate Putamen Thalamus Globus pallidus Frontal Parietal Temporal Occipital
Brain metabolism [18F]FDG − − + NE − − − +
D1 receptors [
11C]SCH 23390 − − NE NE = NE −b NE
D2 receptors [
11C]Raclopride − − NE NE −b NE −b =
Activation of microglia [11C]PK11195 + + = + + + = =
PDE10A [18F]JNJ42259152 − − +a − NE NE NE NE
[18F]MNI-659
[11C]IMA107
A1 adenosine receptors [
18F]CPFPX − − − NE − − − =
CB1 receptors [
18F]MK-9470 − − NE NE NE NE NE NE
OPIOID receptors [11C]Diprenorphine − − + NE + NE − =
GABA receptors [11C]Flumazenil − = = = = = = =
− reduced, + increased, = normal, NE not evaluated
a Evaluated only in preHD
bNot in all the patients
Eur J Nucl Med Mol Imaging (2016) 43:1171–1182 1179
metabolism associated with bilateral decreases in striatal
[18F]FDG binding), postsynaptic dopaminergic function
(reduction in striatal and cortical D1 receptor [
11C]SCH22390
binding andD2 receptor [
11C]raclopride binding) and PDE10A
levels (reduction in striatal and pallidal [11C]IMA107 binding
and increase in motor thalamic nuclei [11C]IMA107 binding)
have been shown to be powerful biomarkers for assessing
progression in patients with manifest HD and also during
premanifest stages. However, no single biomarker may cur-
rently be considered optimal due to specific limitations of each
ligand. An integrated multimodal imaging approach, combin-
ing different techniques, should be developed for evaluating
potential neuroprotective and preventive treatments in HD.
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